Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Double-Blind, Randomized, 8-Week, Vehicle-Controlled Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Adolescents and Adults With Atopic Dermatitis

Next Previous
Trial Profile

A Phase 3, Double-Blind, Randomized, 8-Week, Vehicle-Controlled Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Adolescents and Adults With Atopic Dermatitis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 19 Feb 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ruxolitinib (Primary)
  • Indications Atopic dermatitis
  • Focus Registrational; Therapeutic Use
  • Acronyms TRuE AD1
  • Sponsors Incyte Corporation

    • Most Recent Events

    • 15 Feb 2024 Results of pooled analysis (N=1208) from TRuE-AD1 and TRuE-AD2 studies assessing efficacy and tolerability of ruxolitinib cream published in the Journal of Dermatological Treatment.
    • 01 Dec 2023 Results of post hoc , pooled analysis from TRuE-AD1/TRuE-AD2 , evaluating the efficacy, safety, and disease control of ruxolitinib cream in patients with AD who did not achieve IGA-TS at week 8, published in the Journal of Dermatology
    • 21 Mar 2023 Results of pooled analysis (n=1249 from two studies TRuE-AD1 and TRuE-AD2) assessing the effect of Ruxolitinib Cream Monotherapy Use in Maintenance of Disease and Symptom Control in Adults and Adolescents With Atopic Dermatitis presented at the American Academy of Dermatology annual Meeting 2023
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top